BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 1118487)

  • 21. [BCG-treatment of malignant melanoma].
    Borberg H
    Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254
    [No Abstract]   [Full Text] [Related]  

  • 22. [Immunology of malignant melanoma].
    Misgeld V
    Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321
    [No Abstract]   [Full Text] [Related]  

  • 23. [Immunotherapy].
    Lejeune FJ; Bernheim JL; Vanwijck R
    Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
    [No Abstract]   [Full Text] [Related]  

  • 24. Common human melanoma membrane antigens detected by mixed hemadsorption microassay with serum from a patient undergoing immunotherapy with autologous tumor cells.
    Liao SK; Leong SP; Sutherland CM; Dent PB; Kwong PC; Krementz ET
    Cancer Res; 1978 Dec; 38(12):4395-400. PubMed ID: 82477
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for human malignant melanoma.
    Kopf AW
    South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
    Balzarini GP; Cascinelli N; Fontana V; Veronesi U
    Tumori; 1974; 60(4):345-52. PubMed ID: 4439501
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunofluorescent detection of common melanoma membrane antigens by sera of melanoma patients immunized against autologous or allogeneic cultured melanoma cells.
    Leong SP; Sutherland CM; Krementz ET
    Cancer Res; 1977 Nov; 37(11):4035-42. PubMed ID: 332343
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of recurrent melanoma of the extremity.
    Shingleton WW; Seigler HF; Stocks LH; Downs RW
    Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 31. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of malignancy in humans. Current status.
    Holmes EC; Eilber FR; Morton DL
    JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

  • 36. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
    Svejda J; Mechl Z; Sopková B; Foukal T
    Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunologic reactions in malignant melanoma of the skin in man].
    Veresova OV; Korosteleva TA
    Vopr Onkol; 1975; 21(4):74-80. PubMed ID: 1105967
    [No Abstract]   [Full Text] [Related]  

  • 38. BCG in tumor immunotherapy.
    Baldwin RW; Pimm MV
    Adv Cancer Res; 1978; 28():91-147. PubMed ID: 360797
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.